BioAtla, Inc. (BCAB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09077B1044
BioAtla, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -59.31 m USD |
| EBIT | -60.45 m USD |
| Net income | -59.61 m USD |
| Diluted EPS – continuing operations | -1.01 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
More stocks
- Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192.SS)
- TELEPHONE & DATA SYSTEMS INC /DE/ (TDS)
- SATS Ltd (S58.SI)
- Travel & Leisure Co. (TNL)
- Jersey Mike's Subs Inc. (JMKE)
- Garrett Motion Inc. (GTX)
- Jumbo SA (BELA.AT)
- Faw Car Co Ltd (000800.SZ)
- State Grid Yingda Co Ltd (600517.SS)
- China Cinda Asset Management Co Ltd (1359.HK)
- COMSTOCK RESOURCES INC (CRK)
- Liberty Global Ltd. (LBTYB)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.